CNBC May 30, 2024
Key Points
– The rise of weight loss drugs means consumers’ nutritional needs are “shifting,” Nestle CEO Mark Schneider told CNBC’s Silvia Amaro.
– Nestle is looking to capitalize on the popularity of the GLP-1 drugs with its “ambitious goal to push the healthier products,” the CEO said.
– The Swiss food and beverage giant is set to launch frozen food products targeted at GLP-1 weight loss drug users called Vital Pursuit later this year.
The meteoric rise of weight loss drugs means consumers’ nutritional needs are “shifting” which provides new opportunities for food companies, Nestle CEO Mark Schneider told CNBC.
Investors were initially concerned about the popularity of GLP-1 drugs such as Wegovy and Ozempic as it was assumed...
Today's Sponsors
Today's Sponsor